Natco Pharma launches Xtane

Natco Pharma today announced the launch of Exemestane - a niche product used in the treatment of breast cancer under the brand name Xtane.

Being the first generic launch of Exemestane, Xtane is priced at around 1/6th the price of the innovator brand.

Exemestane would offer a stable and economic option to hormone receptor positive patients who are expected to take the medicine for a minimum period of two years.